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Summary
Background:  Whether  low  molecular  weight  heparin  (LMWH)  enoxaparin  is  equivalent  toUnfractionated
heparin;
Acute
non-ST-segment
elevation  myocardial
infarction;
unfractionated  heparin  (UFH)  in  patients  with  non-ST-segment  elevation  myocardial  infarction
(NSTEMI) undergoing  percutaneous  coronary  intervention  (PCI)  with  drug-eluting  stents  (DES)
remains unclear.
Methods:  A  total  of  2397  NSTEMI  patients  who  underwent  PCI  with  DES  received  either  LMWH
[n =  1178,  subcutaneous  enoxaparin  1  mg/kg,  b.i.d.,  initiated  after  the  patient’s  arrival  and
continued until  3—5  days  after  PCI  plus  reduced  dose  of  UFH  (50—70  U/kg)  during  PCI]  or  UFH
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Antithrombotics  and  drug-eluting  stents  
(n  =  1219,  24,000  U/day  infusion,  i
48 h  after  PCI).  The  bleeding  eve
were compared.
Results:  Enoxaparin  group  had  sim
adverse cardiac  events  (MACE)  at
and minor  bleeding  events  were  al
analysis showed  that  enoxaparin  
ratio (OR)  1.16,  95%  conﬁdence  int
95% CI  0.66—1.76,  p  =  0.760),  and
8 months  as  compared  with  UFH  g
Conclusions:  Enoxaparin  with  red
botic therapy  in  NSTEMI  patients
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Introduction
Previous  studies  suggested  that  the  use  of  enoxaparin
and  aspirin  was  associated  with  improved  outcomes  in
patients  with  non-ST-segment  elevation  myocardial  infarc-
tion  (NSTEMI)  as  compared  with  unfractionated  heparin
(UFH)  and  aspirin  [1].  Therefore,  enoxaparin  is  recom-
mended  for  the  management  of  patients  with  NSTEMI  in  the
current  guidelines  [2].  However,  little  has  been  known  to
date  about  the  optimal  antithrombotic  agent  in  the  setting
of  off-label  use  of  drug-eluting  stents  (DES)  in  patients  with
acute  NSTEMI.  Therefore,  the  present  study  was  aimed  to
compare  the  safety  and  efﬁcacy  of  enoxaparin  with  UFH  in
patients  with  acute  NSTEMI  who  underwent  percutaneous
coronary  intervention  (PCI)  with  DES  in  the  Korea  Acute
Myocardial  Infarction  Registry  (KAMIR).
Methods
KAMIR  study
The  KAMIR  study  is  a  Korean  prospective  multi-center  online
registry  designed  to  reﬂect  the  ‘‘real  world’’  clinical  prac-
tice  in  Asian  patients  with  AMI  in  the  DES  era.  The  study
has  been  supported  by  the  Korean  Circulation  Society  since
November  2005  [3].  A  total  of  41  university  or  community
hospitals  which  were  high-volume  centers  with  facilities
for  primary  PCI  and  on-site  cardiac  surgery  participated  in
this  study.  Data  were  collected  at  each  site  by  a  trained
study  coordinator  using  a  standardized  case  report  form.
Standardized  deﬁnitions  of  all  patient-related  variables
and  clinical  diagnoses  were  used.  The  study  protocol  was
approved  by  the  ethics  committee  and  institutional  review
board  at  each  participating  institution.  Patients  presenting
with  AMI  including  both  ST-segment  elevation  myocardial
infarction  (STEMI)  and  NSTEMI  were  enrolled.
Study  population  and  antithrombotic  regimensFrom  November  2005  to  December  2007,  a  total  of  13,632
patients  were  diagnosed  with  AMI.  In  the  present  study,  the
inclusion  criterion  was  patient  with  NSTEMI  who  underwent
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nitiated  after  the  patient’s  arrival  and  continued  until  at  least
nts  and  clinical  outcomes  during  in-hospital  and  at  8  months
ilar  incidences  of  cardiac  death,  total  death,  and  total  major
 8  months  compared  with  UFH  group.  The  incidences  of  major
so  similar  between  the  two  groups.  Multivariable  Cox  regression
group  had  similar  incidences  of  cardiac  death  [adjusted  odds
erval  (CI)  0.64—2.10,  p  =  0.620],  total  death  (adjusted  OR  1.08,
 total  MACE  (adjusted  OR  0.94,  95%  CI  0.69—1.28,  p  =  0.692)  at
roup.
uced  dose  of  UFH  only  during  PCI  as  an  adjunctive  antithrom-
 undergoing  PCI  with  DES  was  safe  and  showed  comparable
pared  with  UFH  alone.
ology.  Published  by  Elsevier  Ltd.  All  rights  reserved.
CI  with  DES.  The  criteria  for  exclusion  were  STEMI,  NSTEMI
ith  bare  metal  stenting  or  without  stenting,  contraindi-
ation  to  antithrombotic  agents,  known  bleeding  disorders,
hrombocytopenia  (<100  ×  109/L),  administration  of  oral
nticoagulants,  conservative  treatment  without  PCI,  infarc-
ion  related  to  the  grafted  vessel,  and  estimated  life
xpectancy  of  less  than  12  months.
Therefore,  a  total  of  2397  eligible  patients  with  NSTEMI
ho  underwent  PCI  with  DES  were  enrolled  and  divided
nto  two  groups  according  to  the  antithrombotic  thera-
ies:  enoxaparin  group  (n  =  1178)  and  UFH  group  (n  =  1219).
ccording  to  KAMIR  study  design,  the  antithrombotic  ther-
py  started  immediately  after  the  patients’  arrival  in  the
ospitals.  The  patients  in  the  enoxaparin  group  received
ubcutaneous  enoxaparin  1  mg/kg  b.i.d.,  initiated  after  the
atients’  arrival  at  the  hospitals  and  continued  until  3—5
ays  after  PCI.  The  dose  adjustment  of  antithrombotics
as  left  to  the  decision  of  individual  physician,  if  needed.
uring  PCI,  a  reduced  dose  of  UFH  (50  U/kg)  was  given
o  those  who  received  enoxaparin  within  8  h before  PCI
o  maintain  activated  clotting  time  (ACT)  200—300  s,  and
he  usual  dose  of  UFH  was  given  (70  U/kg)  to  those  who
eceived  enoxaparin  beyond  8  h  before  the  procedure  with
he  target  ACT  of  250—300  s.  Patients  in  the  UFH  group
eceived  UFH  24,000  U/day  infusion  after  their  arrival  at
he  hospitals.  During  PCI,  70—100  U/kg  UFH  was  given  to
aintain  the  target  ACT  of  250—300  s.  The  intravenous
nfusion  of  UFH  was  continued  until  at  least  48  h  after
CI,  and  could  be  prolonged  at  the  treating  physician’s
iscretion.
CI  procedure  and  medical  treatment
iagnostic  coronary  angiography  was  performed  via  femoral
r  radial  artery.  During  PCI,  DES  were  deployed  after
redilation  or  thrombus  aspiration.  The  choice  of  DES
epended  upon  the  physician’s  discretion.  The  administra-
ion  of  cilostazol  as  the  third  antiplatelet  agent  (triple
ntiplatelet  therapy)  and  platelet  glycoprotein  IIb/IIIa-
eceptor  blockers  was  left  to  individual  operator’s  decision.
he  successful  PCI  was  deﬁned  as  the  achievement  of  an
ngiographic  residual  stenosis  less  than  30%  in  the  presence
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f  thrombolysis  in  myocardial  infarction  (TIMI)  grade  III
ow.
Loading  doses  of  aspirin  and  clopidogrel  were  adminis-
ered  immediately  after  the  patients  agreed  to  receive  PCI.
he  loading/maintenance  doses  were  200—300  mg/100  mg
.d.  for  aspirin,  and  300—600  mg/75  mg  q.d.  for  clopido-
rel.  Aspirin  and  clopidogrel  were  administered  throughout
he  follow-up  period.  Aspirin  was  recommended  for  life-
ong  administration  and  clopidogrel  for  at  least  1  year.
atients  were  encouraged  to  maintain  the  essential  med-
cations  including  beta-blockers,  angiotensin-converting
nzyme  inhibitors  (ACEIs),  angiotensin  II  receptor  blockers
ARBs)  for  patients  intolerant  to  ACEIs,  and  statins.
tudy  deﬁnitions  and  clinical  follow-up
ll  deaths  were  considered  as  cardiac  death  unless  non-
ardiac  death  could  be  established.  Recurrent  myocardial
nfarction  was  deﬁned  as  the  development  of  either  patho-
ogic  Q  waves  in  at  least  two  contiguous  leads  or  an  increase
n  the  creatine  kinase  level  to  more  than  twice  the  upper
imit  of  normal  with  an  elevation  of  creatine  kinase-MB
soenzyme.  Target  lesion  revascularization  (TLR)  was  deﬁned
s  ischemia  induced  PCI  of  target  lesion  due  to  restenosis
r  reocclusion  within  the  stent  or  in  the  adjacent  5  mm  of
he  distal  or  proximal  segment.  Total  major  adverse  car-
iac  events  (MACE)  were  deﬁned  as  the  composite  of  (1)
otal  death,  (2)  non-fatal  myocardial  infarction  (MI),  and
3)  repeated  PCI  or  coronary  artery  bypass  grafting  (CABG).
ajor  bleeding  was  deﬁned  as  any  intracranial  bleeding,
leeding  associated  with  the  need  for  blood  transfusion,  or
ny  other  clinically  relevant  bleeding  as  judged  by  the  inves-
igator.  Minor  bleeding  was  any  clinically  relevant  bleeding
hat  did  not  qualify  as  major.
All  the  patients  in  the  present  study  received  routine  clin-
cal  follow-up  for  up  to  8  months.  The  incidences  of  major
nd  minor  bleeding  events  and  various  MACE  at  8  months
ere  evaluated  between  the  enoxaparin  group  and  the  UFH
roup.
tatistical  analysis
or  continuous  variables,  differences  between  groups  were
valuated  by  unpaired  t  test  or  Mann—Whitney’s  rank-sum
est.  For  discrete  variables,  differences  were  expressed
s  counts  and  percentages  and  were  analyzed  with  chi-
quare  (or  Fisher  exact)  test  between  groups  as  appropriate.
o  adjust  for  potential  confounders,  a  propensity  score
nalysis  was  performed  by  the  use  of  a  logistic  regres-
ion  model,  testing  the  propensity  to  receive  enoxaparin
ather  than  UFH.  We  tested  all  available  variables  that
e  thought  could  be  relevant  to  the  antithrombotic  ther-
pies:  age,  sex,  Killip  class  on  admission,  cardiovascular
isk  factors  (hypertension,  dyslipidemia,  smoking,  diabetes
ellitus,  family  history  of  coronary  artery  disease),  prior
yocardial  infarction,  chronic  heart  failure,  chronic  renal
isease,  prior  cerebrovascular  disease,  and  peripheral  arte-
ial  disease.  The  logistic  model  by  which  the  propensity
cores  were  estimated  showed  good  predictive  value  (C-
tatistic  =  0.709).  Multivariable  Cox  regression  analysis  was
hen  performed  using  propensity  scores,  antithrombotic
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herapies  (enoxaparin  or  UFH),  the  aforementioned  vari-
bles,  and  treatment  arms  (PCI  or  conservative  therapy),
arget  lesions,  number  of  diseased  vessels,  stent  type,  post-
rocedural  TIMI  blood  ﬂow,  and  cardiovascular  medications
aspirin,  clopidogrel,  cilostazol,  glycoprotein  IIb/IIIa  recep-
or  blockers,  ACEIs,  ARBs,  beta-blockers,  calcium-channel
lockers  (CCBs),  and  statins]  to  ﬁgure  out  the  impact  of
he  different  antithrombotic  regimens  on  the  in-hospital  and
-month  clinical  outcomes.  All  continuous  variables  were
escribed  as  mean  ±  standard  deviation.  All  analyses  were
-tailed,  with  clinical  signiﬁcance  deﬁned  as  p-value  <0.05.
ll  statistical  processes  were  done  using  SPSS  13.0  (Statis-
ical  Package  for  the  Social  Sciences,  SPSS-PC  Inc.  Chicago,
L,  USA).
esults
s  shown  in  Table  1,  baseline  clinical  characteristics  were
imilar  between  the  two  groups  except  that  patients  in  the
noxaparin  group  were  less  likely  to  have  family  history  of
oronary  artery  disease  (CAD)  and  prior  myocardial  infarc-
ion  than  those  in  the  UFH  group.  Patients  in  the  enoxaparin
roup  were  less  likely  to  have  Killip  class  I and  III  cardiac
unction,  but  more  likely  to  have  Killip  class  II than  those  in
he  UFH  group.  Moreover,  patients  in  the  enoxaparin  group
ere  less  likely  to  receive  early  invasive  treatment  than
hose  in  the  UFH  group.
The  baseline  angiographic  and  procedural  characteristics
ere  also  similar  between  the  two  groups  except  that  the
atients  in  the  enoxaparin  group  were  more  likely  to  have
ower  grades  of  baseline  TIMI  blood  ﬂow,  and  more  likely  to
eceive  sirolimus-eluting  stents  than  those  in  the  UFH  group
Table  2).
The  in-hospital  medications  are  listed  in  Table  3.  Patients
n  the  enoxaparin  group  had  lower  administration  rates
f  cilostazol,  beta-blockers,  ACEIs,  CCBs  and  statins,  and
 trend  toward  lower  administration  rate  of  glycoprotein
Ib/IIIa  receptor  blockers  than  those  in  the  UFH  group.  But,
atients  in  the  enoxaparin  group  had  a  higher  use  rate  of
RBs  than  those  in  the  UFH  group.
In-hospital  clinical  outcomes  showed  that  the  enoxaparin
roup  had  similar  incidences  of  cardiac  death,  total  death,
ajor  and  minor  bleeding  events  as  compared  with  the  UFH
roup  (Table  4).  The  clinical  outcomes  at  8  months  showed
hat  the  enoxaparin  group  had  similar  incidences  of  cardiac
eath,  total  death,  and  total  MACE  as  compared  with  the
FH  group.  Despite  the  similar  incidence  of  repeated  PCI,
he  enoxaparin  group  had  a  signiﬁcantly  lower  incidence  of
LR  and  recurrent  myocardial  infarction  than  the  UFH  group.
he  incidence  of  CABG  was  similar  between  these  two  groups
Table  4).
Multivariable  Cox  regression  analysis  showed  that  the
noxaparin  group  had  similar  incidences  of  in-hospital  car-
iac  death  and  total  death  as  compared  with  the  UFH  group.
he  adjusted  clinical  outcomes  at  8  months  showed  that
oth  the  enoxaparin  group  and  the  UFH  group  had  similar
ncidences  of  cardiac  death,  total  death,  CABG,  repeated
CI,  and  total  MACE.  However,  the  enoxaparin  group  had
 signiﬁcantly  lower  incidence  of  TLR,  and  a  trend  toward
ower  incidence  of  recurrent  myocardial  infarction  as  com-
ared  with  the  UFH  group  (Table  5  and  Fig.  1).
Antithrombotics  and  drug-eluting  stents  25
Table  1  Baseline  clinical  characteristics.
Variables,  n  (%)  UFH  (n  =  1219)  Enoxaparin  (n  =  1178)  p-Value
Age,  years  63.73  ±  11.91  63.77  ±  11.37  0.925
Body mass  index,  kg/m2 24.22  ±  3.07  24.10  ±  3.06  0.370
Male 847  (69.5)  794  (67.4)  0.273
Past history
Hypertension  643  (52.7)  651  (55.3)  0.217
Diabetes mellitus  376  (30.8)  391  (33.2)  0.218
Current smoking  482  (39.5)  458  (38.9)  0.740
Dyslipidemia 164  (13.5) 148  (12.6) 0.517
Family history  of  CAD 115  (9.4) 51  (4.3) <0.001
Prior myocardial  infarction 122  (10.0) 82  (7.0) 0.008
Chronic heart  failure 30  (2.5)  36  (3.1)  0.373
Peripheral artery  disease  19  (1.6)  15  (1.3)  0.555
Cerebrovascular  disease 90  (7.4)  94  (8.0)  0.583
Peptic ulcer  disease 3  (0.2) 4  (0.3)  0.722
Chronic renal  disease 29  (2.4) 39  (3.3)  0.170
Killips class  on  admission <0.001
Class  I 973  (79.8) 912  (77.4)
Class II 111  (9.1) 172  (14.6)
Class III 112  (9.2) 73  (6.2)
Class IV 23  (1.9) 21  (1.8)
Early invasive  treatment 745  (61.1) 560  (47.5) <0.001
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Discussion
The  major  ﬁnding  of  the  present  study  is  that  the  treat-
ment  with  either  subcutaneous  enoxaparin  combined  with
reduced  dose  of  UFH  only  during  PCI  or  UFH  alone  had  similar
safety  proﬁles  including  major  and  minor  bleeding  events,
and  efﬁcacy  proﬁles  including  mortality  and  total  MACE  dur-
ing  the  in-hospital  period  and  at  8  months.
DES  were  proclaimed  as  ‘‘revolutionary  devices’’
because  of  their  ability  to  dramatically  reduce  the
angiographic  restenosis  rate  and  the  need  for  repeated
revascularization  procedures  as  compared  with  bare  metal
stents  [4].  The  off-label  use  of  DES  has  increased  steadily
since  their  introduction  [3,5,6]. In  non-ST-elevation  acute
coronary  syndromes  (ACS),  the  use  of  DES  has  been  reported
to  be  nearly  80%  [7].  However,  concerns  have  been  raised
about  the  safety  of  DES  in  patients  with  AMI  [8—10]. Sev-
eral  registry  studies  showed  that  the  DES  implantation  in
the  AMI  setting  was  associated  with  an  increased  risk  for
acute  and  subacute  stent  thrombosis  [11—13]. Other  stud-
ies  showed  that  an  altered  environment  with  high  thrombin
activity  and  marked  increased  platelet  reactivity  was  seen
in  the  early  period  of  AMI  in  patients  undergoing  primary  PCI
[14—16].  Therefore,  proper  antithrombotic  and  antiplatelet
regimens  would  be  crucial  for  the  patient  with  AMI  undergo-
ing  PCI  with  DES.  However,  little  is  known  about  the  optimal
dosage  and  type  of  antithrombotics  in  this  clinical  setting  to
date.
Low-molecular  weight  heparin  (LMWH)  has  been  demon-
strated  to  have  several  well-established  advantages  over
UFH  as  a  sole  antithrombotic  agent  [12]. LMWH  has  a  more
predictable  pharmacological  proﬁle  than  UFH,  removing  the
need  for  close  therapeutic  drug  monitoring  [17]. In  contrast,
A
a
p
tFH  shows  an  unpredictable  pharmacological  proﬁle  which
eeds  close  monitoring  of  anticoagulation  levels.  In  addi-
ion,  UFH  shows  prothrombotic  properties  related  to  poor
ontrol  of  von  Willebrand  factor  release,  as  well  as  platelet
ctivation  and  rebound  of  thrombin  generation  after  discon-
inuation  [15,17,18].
The comparisons  between  UFH  and  enoxaparin  in  the
atients  with  non-ST-elevation  ACS  have  been  reported
n  several  previous  studies  [1,19]. Efﬁcacy  and  Safety  of
ubcutaneous  Enoxaparin  in  Non-Q-Wave  Coronary  Events
ESSENCE)  [19]  and  Thrombolysis  in  Myocardial  Infarction-
1B  [1]  studies  compared  the  use  of  enoxaparin  with  UFH  in
atients  with  non-ST-elevation  ACS,  and  showed  that  the  use
f  enoxaparin  was  associated  with  a  16%  reduction  in  14-day
ortality,  recurrent  myocardial  infarction,  and  recurrent
schemia.  Because  of  these  encouraging  results,  enoxaparin
s  recommended  for  the  management  of  patients  with  acute
STEMI  in  the  current  guidelines  [2].
However,  in  contrast  to  these  studies,  the  present  study
howed  that  compared  with  UFH,  enoxaparin  showed  sim-
lar  safety  and  efﬁcacy  proﬁles  during  in-hospital  period
nd  at  8  months.  Furthermore,  our  results  were  consis-
ent  with  some  other  studies  which  also  compared  the
afety  and  efﬁcacy  of  enoxaparin  and  UFH  in  the  setting
f  non-ST-elevation  ACS.  Eikelboom  et  al.  [20]  performed
 meta-analysis  including  12  randomized  trials  with  17,157
atients  to  compare  UFH  or  enoxaparin  with  placebo  or
ntreated  control,  or  comparing  UFH  with  enoxaparin,  for
he  short-term  and  long-term  management  of  patients  with
CS  without  ST  elevation.  Their  results  showed  that  in
spirin-treated  patients  with  ACS,  short-term  UFH  or  enoxa-
arin  halved  the  risk  of  myocardial  infarction  or  death,  and
here  was  no  convincing  difference  in  efﬁcacy  or  safety
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Table  2  Baseline  angiographic  and  PCI  procedural  characteristics.
Variables,  n  (%)  UFH  (n  =  1219)  Enoxaparin  (n  =  1178)  p-Value
Target  lesion  0.964
LAD 511  (41.9)  482  (40.9)
RCA 338  (27.7)  333  (28.3)
LCX 335  (27.5)  330  (28.0)
Left main  35  (2.9)  33  (2.8)
Number of  diseased  vessels 0.563
Single-vessel  disease 421  (34.5) 399  (33.9)
Two-vessel  disease 429  (35.2) 399  (33.9)
Three-vessel  disease 323  (26.5) 344  (29.2)
Left main  disease  46  (3.7)  36  (3.0)
Pre-procedure  TIMI  ﬂow  <0.001
TIMI 0 307  (25.2)  330  (28.0)
TIMI I  129  (10.5)  173  (14.7)
TIMI II  263  (21.6)  208  (17.7)
TIMI III  520  (42.7)  467  (39.6)
Stent type  <0.001
Sirolimus-eluting  stent  533  (43.7)  624  (53.0)
Paclitaxel-eluting  stent  486  (39.9)  378  (32.1)
Zotarolimus-eluting  stent  78  (6.4)  73  (6.2)
Other drug-eluting  stent  122  (10.0)  103  (8.7)
Stent diameter,  mm 3.10  ±  0.37  3.08  ±  0.41  0.127
Stent length,  mm  25.04  ±  6.47  25.45  ±  6.43  0.115
Stent number  per  patient 1.74  ±  0.97  1.75  ±  0.89  0.854
Post-procedure  TIMI  ﬂow 0.219
TIMI  0 3  (0.2)  7  (0.6)
TIMI I  7  (0.6)  2  (0.2)
TIMI II 20  (1.6)  21  (1.8)
TIMI III 1189  (97.6) 1148  (97.5)
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aTIMI, thrombolysis in myocardial infarction; LAD, left anterior desc
UFH, unfractionated heparin.
etween  enoxaparin  and  UFH.  Similarly,  in  the  Superior
ield  of  the  New  Strategy  of  Enoxaparin,  Revascularization,
nd  Glycoprotein  IIb/IIIa  Inhibitors  (SYNERGY)  trial  [21], a
otal  of  10,027  patients  with  non-ST-elevation  ACS  under-
oing  intended  early  invasive  strategy  were  randomized  to
eceive  enoxaparin  or  UFH,  and  the  results  showed  that  the
rimary  composite  30-day  end  point  of  all-cause  death  or
onfatal  myocardial  infarction  occurred  in  14.0%  of  patients
reated  with  enoxaparin  and  14.5%  of  patients  with  UFH
p  >  0.05).  In  addition,  the  use  of  enoxaparin  was  associated
4
i
S
p
Table  3  In-hospital  medications.
Variables,  n  (%)  UFH  (n  =  1219)  
Aspirin 1210 (99.3)  
Clopidogrel 1208 (99.1)  
Cilostazol 551  (45.2)  
GP IIb/IIIa  receptor  blocker  157  (12.9)  
Beta-blockers  989  (81.1)  
ACEIs 951  (78.0)  
ARBs 168  (13.8)  
Calcium channel  blockers  233  (19.1)  
Statins 990  (81.2)  
GP, glycoprotein; ACEIs, angiotensin-converting enzyme inhibitors; ARBng artery; RCA, right coronary artery; LCX, left circumﬂex artery;
ith  a  signiﬁcantly  higher  incidence  of  TIMI  severe  bleeding.
hus,  the  SYNERGY  trial  suggested  that  LMWH  enoxaparin
as  similar  to  UFH  for  the  treatment  of  high-risk  patients
ith  non-ST-segment  elevation  ACS.  Recently,  Murphy  et  al.
22]  also  performed  a  meta-analysis  of  randomized  tri-
ls  of  enoxaparin  versus  UFH  in  12  trials  with  a  total  of
9,088  patients  with  ACS.  They  showed  that  the  net  clin-
cal  beneﬁt  in  favor  of  enoxaparin  was  evident  among  the
TEMI  population  but  was  neutral  among  the  other  ACS
opulation.
Enoxaparin  (n  =  1178)  p-Value
1174  (99.7)  0.184
1169 (99.2)  0.710
333  (28.3)  <0.001
122  (10.4)  0.054
841  (71.4)  <0.001
749  (63.6)  <0.001
229  (19.4)  <0.001
171  (14.5)  0.003
828  (70.3)  <0.001
s, angiotensin II receptor blockers; UFH, unfractionated heparin.
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Table  4  Cumulative  clinical  outcomes  up  to  8  months.
Variables,  n  (%) UFH  (n  =  1219)  Enoxaparin  (n  =  1178)  p-Value
In-hospital  outcomes
Cardiac  death  12  (1.0)  15  (1.3)  0.503
Total death  16  (1.3)  20  (1.7)  0.438
Major bleeding  events  3  (0.2)  4  (0.3)  0.672
Minor bleeding  events 11  (0.9)  13  (1.1)  0.621
Outcomes at  8  months
Cardiac  death 22 (1.8)  29 (2.5)  0.265
Total death 33 (2.7)  41 (3.5)  0.274
Recurrent MI 12 (1.0)  3 (0.3)  0.024
CABG 3  (0.2)  3  (0.3)  1.000
Repeated PCI 43  (3.5)  42  (3.6)  0.960
TLR 25  (2.1)  10  (0.8)  0.014
Total MACE 92 (7.5)  89 (7.6)  0.994
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mCABG, coronary artery bypass grafting; MACE, major adverse ca
intervention; TLR, target lesion revascularization; UFH, unfractio
However,  it  should  be  specially  pointed  out  that  none  of
the  aforementioned  studies  [1,19—22]  had  compared  enoxa-
parin  with  UFH  in  the  patients  with  NSTEMI  undergoing  PCI
with  DES.  For  fear  of  higher  probability  of  catheter  throm-
bosis  and  stent  thrombosis  after  DES  implantation  in  NSTEMI
setting,  enoxaparin  group  received  reduced  dose  of  UFH
(50—70  U/kg)  only  during  PCI  [23]. Therefore,  from  this  point
of  view,  the  present  study  is  the  ﬁrst  study  to  compare
enoxaparin  plus  reduced  dose  of  UFH  (50—70  U/kg)  only  dur-
ing  PCI  with  UFH  alone  in  the  setting  of  off-label  use  of
DES  in  acute  NSTEMI  patients.  Interestingly,  although  the
two  groups  had  similar  incidences  of  8-month  cardiac  death,
total  death,  and  total  MACE,  the  enoxaparin  group  had  a  sig-
niﬁcantly  lower  incidence  of  TLR  and  a  trend  toward  lower
incidence  of  recurrent  myocardial  infarction.  It  should  be
noted  that  patients  in  the  UFH  group  received  more  car-
diovascular  beneﬁcial  medications  as  compared  with  those
in  the  enoxaparin  group,  suggesting  the  possibility  that  the
superiority  of  enoxaparin  may  be  offset  by  the  lower  use
rates  of  these  drugs.  Meanwhile,  patients  in  the  enoxaparin
o
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Table  5  Adjusted  cumulative  clinical  outcomes  after  up  to  8  mon
regression analysis  using  propensity  score).
Variables  Unadjusted  OR  (95%  CI)  p
In-hospital  outcomes
Cardiac  death  1.30  (0.61—2.78)  0
Total death  1.30  (0.67—2.52)  0
Outcomes at  8  months
Cardiac  death  1.37  (0.78—2.40)  0
Total death  1.30  (0.81—2.06)  0
Recurrent MI  0.26  (0.07—0.91)  0
CABG 1.03  (0.21—5.14)  0
Re-PCI 1.01  (0.66—1.56)  0
TLR 0.41  (0.20—0.85)  0
Total MACE  1.00  (0.74—1.36)  0
CABG, coronary artery bypass graft; CI, conﬁdence interval; MACE, ma
ratio; PCI, percutaneous coronary intervention; TLR, target lesion reva events; MI, myocardial infarction; PCI, percutaneous coronary
 heparin.
roup  had  a  higher  rate  of  sirolimus-eluting  stent  (SES)
mplantation.  Some  previous  studies  have  suggested  that
ES  is  superior  to  paclitaxel-eluting  stent  (PES)  in  terms
f  reducing  the  incidence  of  TLR  [24]. We  suppose  that
he  advantage  of  SES  over  PES  in  reducing  TLR  might  have
verwhelmed  the  beneﬁcial  effects  from  the  other  medical
reatments.
tudy  strengths  and  limitations
he  strengths  of  the  KAMIR  study  included  its  prospective
esign  and  large  multicenter  population  base.  The  registry
rovides  a  comprehensive  view  of  the  contemporary  treat-
ents  and  outcomes  in  the  Asian  patients  with  AMI  in  the  era
f  DES.  The  DES  penetration  in  AMI  setting  is  approximately
3%  in  Korea,  thus  virtually  all  patients  could  be  enrolled
onsecutively,  reﬂecting  current  real  world  clinical  practice
3,5].
ths  of  enoxaparin  compared  with  unfractionated  heparin  (Cox
-Value  Adjusted  OR  (95%  CI)  p-Value
.504  0.81  (0.36—1.84)  0.614
.439  0.84  (0.41—1.71)  0.631
.267  1.16  (0.64—2.10)  0.620
.275  1.08  (0.66—1.76)  0.760
.036  0.33  (0.09—1.22)  0.096
.967  0.61  (0.11—3.46)  0.578
.960  1.04  (0.66—1.64)  0.872
.018  0.45  (0.21—0.99)  0.046
.994  0.94  (0.69—1.28)  0.692
jor adverse cardiac events; MI, myocardial infarction; OR, odds
scularization.
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Figure  1  Adjusted  cumulative  incidences  in  patients  receiv-
ing enoxaparin  or  UFH  of  cardiac  death  (A),  total  death  (B),
and total  MACE  (C)  at  8  months.  Cum.  Prob.,  cumulative  prob-
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Rbility;  OR,  odds  ratio;  CI,  conﬁdence  interval;  MACE,  major
dverse  cardiac  events;  UFH,  unfractionated  heparin.
However,  the  present  study  also  had  some  limita-
ions.  First,  although  there  were  a  relatively  large  number
f  patients  in  the  present  study,  because  of  the  non-
andomized  nature  of  the  registry  study,  there  were  baseline
ifferences  in  several  important  prognostic  factors  between
ur  primary  comparison  groups.  Although  we  included  most
onfounders  in  the  multivariable  Cox  regression  model
ncluding  propensity  scores  to  control  the  baseline  biases,
t  is  possible  that  some  potential  confounders  might  have
rept  in.  Nevertheless,  this  multicenter  registry  may  help
s  to  complete  the  picture  gained  from  randomized  trials
hich  usually  have  highly  selected  patients  treated  in  a
on-routine  setting.  Second,  although  the  antithrombotic
egimens  were  prospectively  designed  in  the  KAMIR  study,
e  did  not  have  detailed  information  about  the  activated
artial  thromboplastin  time  achieved  with  UFH,  and  the
xact  use  period  of  the  heparins,  all  factors  that  might  have
nﬂuenced  the  rate  of  clinical  events.  However,  the  potential
ifferences  in  the  duration  of  treatment  reﬂect  the  ‘‘real
orld’’  clinical  practice.  Third,  because  this  study  is  not  aY.-J.  Li  et  al.
esigned  randomized  study,  the  enoxaparin  group  received
FH  during  PCI  in  most  of  the  participating  centers.  Thus  we
annot  do  a  head-to-head  comparison  between  enoxaparin
lone  versus  UFH  alone  from  our  study  population.  Further-
ore,  in  the  enoxaparin  group,  the  effects  of  reduced  dose
f  UFH  during  PCI  on  the  clinical  outcomes  remain  unclear.
owever,  due  to  the  short  use  period,  we  suppose  the  effects
f  its  use  might  be  limited.
onclusions
he  present  study  suggests  that  antithrombotic  therapy
ither  with  subcutaneous  LMWH  enoxaparin  1  mg/kg  b.i.d.
lus  reduced  dose  of  UFH  (50—70  U/kg)  during  PCI  or  UFH
lone  are  comparable  as  an  adjunctive  antithrombotic  ther-
py  for  patients  with  NSTEMI  undergoing  PCI  with  DES.  These
esults  might  provide  the  rationale  for  the  administration
f  either  of  these  two  different  antithrombotic  regimens  in
hese  patients.  However,  due  to  the  limitation  of  the  reg-
stry  study,  a  further  randomized  trial  with  a  larger  study
opulation  will  be  needed  to  make  the  ﬁnal  conclusions.
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